ES2464777T3 - Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo - Google Patents

Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo Download PDF

Info

Publication number
ES2464777T3
ES2464777T3 ES08153854.8T ES08153854T ES2464777T3 ES 2464777 T3 ES2464777 T3 ES 2464777T3 ES 08153854 T ES08153854 T ES 08153854T ES 2464777 T3 ES2464777 T3 ES 2464777T3
Authority
ES
Spain
Prior art keywords
protein
solution
column
tat
hoxb4h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08153854.8T
Other languages
English (en)
Inventor
Kou-Juey Wu
Chi-Hung Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAIWAN ADVANCE BIO-PHARM Inc
Taiwan Advance Bio Pharm Inc
Original Assignee
TAIWAN ADVANCE BIO-PHARM Inc
Taiwan Advance Bio Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAIWAN ADVANCE BIO-PHARM Inc, Taiwan Advance Bio Pharm Inc filed Critical TAIWAN ADVANCE BIO-PHARM Inc
Application granted granted Critical
Publication of ES2464777T3 publication Critical patent/ES2464777T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Water Supply & Treatment (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un metodo de produccion de una proteina TAT-HOXB4H que comprende: (a) proporcionar una celula huesped que comprende un vector que codifica la proteina de fusion TAT-HOXB4 etiquetada con histidina de terminal C (TAT-HOXB4H) que contiene por lo menos 6 residuos de histidina en el terminal C; (b) expresar la proteina en la celula huesped; (c) recoger una solucion impura de la proteina expresada; (d) purificar la proteina de la solucion mediante: (i) aplicar la solucion a una columna de HisTrap; (ii) lavar la columna de la HisTrap; (iii) eluir la proteina parcialmente purificada de la columna de HisTrap para formar una solucion de proteina parcialmente purificada; (iv) la aplicacion de la solucion de proteina parcialmente purificada a una columna de MonoSP; (v) lavar la columna de la MonoSP; (vi) eluir la proteina purificada a partir de la columna de la MonoSP en forma desnaturalizada; (e) el replegamiento de la proteina desnaturalizada eluida utilizando compuestos hidrofobos mediante.

Claims (1)

  1. REIVINDICACIONES
ES08153854.8T 2008-03-04 2008-03-31 Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo Active ES2464777T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42097 2008-03-04
US12/042,097 US8222206B2 (en) 2008-03-04 2008-03-04 Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H

Publications (1)

Publication Number Publication Date
ES2464777T3 true ES2464777T3 (es) 2014-06-04

Family

ID=40627112

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12152269.2T Active ES2567780T3 (es) 2008-03-04 2008-03-31 Método para la producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo
ES08153854.8T Active ES2464777T3 (es) 2008-03-04 2008-03-31 Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12152269.2T Active ES2567780T3 (es) 2008-03-04 2008-03-31 Método para la producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo

Country Status (15)

Country Link
US (4) US8222206B2 (es)
EP (2) EP2100968B1 (es)
JP (2) JP4755224B2 (es)
KR (1) KR101160381B1 (es)
CN (3) CN104650210B (es)
BR (1) BRPI0803381A2 (es)
CA (1) CA2658231C (es)
ES (2) ES2567780T3 (es)
HK (2) HK1130290A1 (es)
HU (1) HUE027513T2 (es)
MY (1) MY164521A (es)
PL (2) PL2100968T3 (es)
PT (1) PT2100968E (es)
RU (1) RU2401863C2 (es)
TW (1) TWI414598B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
US10896327B1 (en) 2013-03-15 2021-01-19 Spatial Cam Llc Device with a camera for locating hidden object
US10354407B2 (en) 2013-03-15 2019-07-16 Spatial Cam Llc Camera for locating hidden objects
JP6030114B2 (ja) * 2011-03-22 2016-11-24 プルリステム リミテッド 放射線照射または化学物質による傷害を治療するための方法
RU2495125C2 (ru) * 2011-12-07 2013-10-10 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт патологии кровообращения имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИПК им. акад. Е.Н. Мешалкина" Минздрава России) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pOK-DsRed2, КОДИРУЮЩАЯ БЕЛКИ ОСТ4 И KLF4 ЧЕЛОВЕКА И ФЛУОРЕСЦЕНТНЫЙ БЕЛОК DsRed2, ПРЕДНАЗНАЧЕНАЯ ДЛЯ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК ЧЕЛОВЕКА
CN105051061B (zh) * 2013-01-30 2020-02-21 康奈尔大学 用于扩增干细胞的组合物和方法
EP3290047A1 (en) * 2013-04-05 2018-03-07 Claudia Zylberberg Matrix metalloproteinases and uses thereof
TWI548748B (zh) * 2015-04-16 2016-09-11 台灣尖端先進生技醫藥股份有限公司 造血幹／先驅細胞之體外放大培養方法及其立即可使用之組成物
WO2017143210A1 (en) * 2016-02-19 2017-08-24 The General Hospital Corporation Methods for generating universal and custom mhc/hla-compatible hematopoietic progenitor cells
JP7304405B2 (ja) 2018-09-24 2023-07-06 ボストン サイエンティフィック サイムド，インコーポレイテッド 組織保持力を向上させたアグレッシブな機能クリップ
TW202026307A (zh) * 2019-01-11 2020-07-16 台灣尖端先進生技醫藥股份有限公司 Ｎ－端標記組胺酸之重組ｔａｔ－ｈｏｘ家族蛋白質及其製造方法
TWI756518B (zh) * 2019-02-27 2022-03-01 台灣尖端先進生技醫藥股份有限公司 突變型ｈｏｘｂ４重組蛋白質之製造方法與用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2838867B2 (ja) * 1986-01-22 1998-12-16 中外製薬株式会社 幹細胞増殖促進剤
JPH0276820A (ja) * 1988-06-15 1990-03-16 Ajinomoto Co Inc 骨髄移植療法支持剤
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5837507A (en) 1995-11-13 1998-11-17 The Regents Of The University Of California Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods
US6303337B1 (en) * 1999-08-25 2001-10-16 Amber Gen. Inc. N-terminal and C-terminal markers in nascent proteins
US20020086383A1 (en) 2000-02-23 2002-07-04 Guy Sauvageau Hematopoietic stem cell expansion enhancing factor and method of use
US20040072298A1 (en) 2000-02-23 2004-04-15 Guy Sauvageau Stem cell expansion enhancing factor and method of use
US20040082003A1 (en) 2000-02-23 2004-04-29 Guy Sauvageau Stem cell expansion enhancing factor and method of use
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
CN102061288A (zh) * 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
JP2006501829A (ja) * 2002-10-08 2006-01-19 アンスティテュ ドゥ ルシェルシュ クリニーク ドゥ モレアル Ｈｏｘで誘導される増殖を制限する遺伝子をブロックする幹細胞増殖因子およびその方法
US20040229330A1 (en) 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
JP5517394B2 (ja) * 2003-07-03 2014-06-11 ユニバーシティ オブ サザン カリフォルニア 造血におけるｉｌ−１２の使用
WO2005026196A2 (en) 2003-09-12 2005-03-24 Novexin Limited Methods for folding proteins and reducing protein aggregation
TW200517398A (en) 2003-11-21 2005-06-01 Ind Tech Res Inst Method for recombinant protein purification, modification and immobilization
CA2573176A1 (en) * 2004-07-09 2006-01-19 Bc Cancer Agency Nup98-hox fusions for expansion of hemopoietic stem cells
TWI328036B (en) * 2005-07-01 2010-08-01 Taiwan Advance Bio Pharm Inc Process for producing c-termial histidine tagged hoxb4 and the use thereof in expanding stem cells
CN101016540B (zh) 2006-02-10 2010-04-07 台湾尖端先进生技医药股份有限公司 C-端含有组氨酸标记的hoxb4重组蛋白质的制造方法及用途
CN101528915A (zh) 2006-04-14 2009-09-09 先进细胞技术公司 血管瘤集落形成细胞
TWI311562B (en) 2006-05-09 2009-07-01 Northern Taiwan Bio Pharm Inc One step rapid desalting and protein refolding process
TWI369990B (en) 2006-09-05 2012-08-11 Taiwan Advance Bio Pharminc Hsc proliferated with c-histidine labeled hoxb4h and use thereof
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H

Also Published As

Publication number Publication date
EP2100968B1 (en) 2014-02-26
CA2658231C (en) 2014-09-23
CN101524527A (zh) 2009-09-09
US20110092450A1 (en) 2011-04-21
TW200938632A (en) 2009-09-16
CN104650210A (zh) 2015-05-27
TWI414598B (zh) 2013-11-11
PL2100968T3 (pl) 2014-08-29
HK1130290A1 (en) 2009-12-24
BRPI0803381A2 (pt) 2011-08-23
JP5738636B2 (ja) 2015-06-24
US8124377B2 (en) 2012-02-28
EP2100968A1 (en) 2009-09-16
RU2401863C2 (ru) 2010-10-20
CN101524527B (zh) 2016-06-01
JP2009207482A (ja) 2009-09-17
US20120322979A1 (en) 2012-12-20
US8222207B2 (en) 2012-07-17
US8222206B2 (en) 2012-07-17
JP2011168597A (ja) 2011-09-01
MY164521A (en) 2017-12-29
US20110092412A1 (en) 2011-04-21
HK1170933A1 (zh) 2013-03-15
RU2008134247A (ru) 2010-02-27
US20090227496A1 (en) 2009-09-10
CN102805859B (zh) 2016-06-01
CN104650210B (zh) 2018-01-23
EP2455099B1 (en) 2016-01-20
PT2100968E (pt) 2014-05-30
KR101160381B1 (ko) 2012-06-26
CN102805859A (zh) 2012-12-05
EP2455099A1 (en) 2012-05-23
ES2567780T3 (es) 2016-04-26
US8450458B2 (en) 2013-05-28
HUE027513T2 (en) 2016-10-28
PL2455099T3 (pl) 2016-07-29
CA2658231A1 (en) 2009-09-04
KR20090095473A (ko) 2009-09-09
JP4755224B2 (ja) 2011-08-24

Similar Documents

Publication Publication Date Title
ES2464777T3 (es) Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
ES2492681T3 (es) Método cromatográfico para purificar proteínas que contienen FC
RU2012108039A (ru) Хроматографические способы и соединения, очищенные этими способами
NZ630848A (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
UA100901C2 (ru) Способ очищения фактора свертывания крови viii
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
AR070119A1 (es) Derivados de insulina con perfil tiempo / accion extremadamente retardado
AR062570A1 (es) Proceso para la purificacion de las proteinas que contienen fc
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
PH12013501128A1 (en) Antibody purification by cation exchange chromatography
PE20090726A1 (es) Anticuerpos anti-ige apoptoticos
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
EA201171199A1 (ru) Способ очистки рекомбинантного фсг
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
CL2009000210A1 (es) Acidos nucleicos que comprenden una secuencia que codifica un peptido de transito a plastidios de una glaucosafita enlazada a una segunda secuencia que codifica un peptido heterologo; metodo para la expresion estable de un polipeptido heterologo en una planta; polipeptido aislado codificado por el acido nucleico descrito anteriormente.
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
ECSP12011577A (es) Produccion recombinante de péptidos
DK2132316T3 (da) Forøget amylaseproduktion ved n-terminal addition til modent amylaseprotein
IN2014DN09815A (es)